Free Trial
NASDAQ:ABVC

ABVC BioPharma Q2 2025 Earnings Report

ABVC BioPharma logo
$1.10 -0.01 (-0.45%)
As of 12:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ABVC BioPharma EPS Results

Actual EPS
-$0.13
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ABVC BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ABVC BioPharma Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Wednesday, August 13, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

ABVC BioPharma's Q1 2026 earnings is estimated for Tuesday, May 19, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, May 14, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

ABVC BioPharma Earnings Headlines

ABVC BioPharma Reports 2025 Form 10-K
ABVC BioPharma Provides Corporate and Structural Update
Massive Data Leak Exposes 512,000-Line Code That Could Change Society Forever
"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent traveled to Lower Manhattan for a sit-down interview with 60-year Wall Street legend Marc Chaikin, she was shocked to discover that Marc had prepared a live demonstration of a technology that could change society forever. It involves NASA, the Department of Defense, huge banks – and a MAJOR AI upgrade that could add $400 trillion to the global economy.tc pixel
See More ABVC BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ABVC BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ABVC BioPharma and other key companies, straight to your email.

About ABVC BioPharma

ABVC BioPharma (NASDAQ:ABVC) is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens. ABVC BioPharma applies its platform to generate both personalized and off-the-shelf candidates, with preclinical and early-stage clinical studies evaluating safety, immunogenicity and preliminary efficacy.

Headquartered in Research Triangle Park, North Carolina, ABVC BioPharma operates research laboratories in North America and collaborates with academic and industry partners to advance its development programs. The company’s leadership team is composed of executives and scientists with experience in peptide chemistry, immunology and clinical development, guiding its efforts to bring new vaccine-based therapies to market.

View ABVC BioPharma Profile